2013
Predictors of suboptimal TIMI flow after primary angioplasty for acute myocardial infarction: results from the HORIZONS-AMI trial.
Caixeta A, Lansky AJ, Mehran R, Brener SJ, Claessen B, Généreux P, Palmerini T, Witzenbichler B, Guagliumi G, Brodie BR, Dudek D, Fahy M, Dangas GD, Stone GW. Predictors of suboptimal TIMI flow after primary angioplasty for acute myocardial infarction: results from the HORIZONS-AMI trial. EuroIntervention 2013, 9: 220-7. PMID: 23518872, DOI: 10.4244/eijv9i2a37.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAngioplasty, Balloon, CoronaryAntithrombinsChi-Square DistributionCoronary AngiographyCoronary CirculationFemaleHumansKaplan-Meier EstimateLogistic ModelsMaleMiddle AgedMyocardial InfarctionOdds RatioPlatelet Aggregation InhibitorsPredictive Value of TestsProportional Hazards ModelsProspective StudiesRecovery of FunctionRisk FactorsTime FactorsTreatment OutcomeConceptsTIMI 3 flowFinal TIMI 3 flowHORIZONS-AMI trialAcute myocardial infarctionPrimary PCITIMI flowMyocardial infarctionGlycoprotein IIb/IIIa inhibitorsIIb/IIIa inhibitorsNormal TIMI flowThree-year mortalityMulticentre prospective studyPatient-related factorsBaseline TIMIAngiographic factorsPrimary angioplastyIndependent predictorsUnfractionated heparinProspective studyAnterior MIAnatomical factorsPatientsTIMICore labLesion length
2012
Clinical Outcomes Following Stent Thrombosis Occurring In-Hospital Versus Out-of-Hospital Results From the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) Trial
Dangas GD, Claessen BE, Mehran R, Brener S, Brodie BR, Dudek D, Witzenbichler B, Peruga JZ, Guagliumi G, Moses JW, Lansky AJ, Xu K, Stone GW. Clinical Outcomes Following Stent Thrombosis Occurring In-Hospital Versus Out-of-Hospital Results From the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) Trial. Journal Of The American College Of Cardiology 2012, 59: 1752-1759. PMID: 22575312, DOI: 10.1016/j.jacc.2011.12.042.Peer-Reviewed Original ResearchConceptsST-segment elevation myocardial infarctionHospital stent thrombosisPrimary percutaneous coronary interventionGlycoprotein IIb/IIIa inhibitorsHORIZONS-AMI trialStent thrombosisMajor bleedingClinical outcomesUnfractionated heparinMyocardial infarctionST eventsPrimary PCIIIb/IIIa inhibitorsProbable stent thrombosisAcademic Research ConsortiumElevation myocardial infarctionPercutaneous coronary interventionSTEMI patientsCoronary interventionHospital phaseBetter prognosisMultivariable analysisReperfusion resultsSubgroup analysisMost deaths
2011
Impact of Smoking on Outcomes of Patients With ST-Segment Elevation Myocardial Infarction (from the HORIZONS-AMI Trial)
Goto K, Nikolsky E, Lansky AJ, Dangas G, Witzenbichler B, Parise H, Guagliumi G, Kornowski R, Claessen BE, Fahy M, Mehran R, Stone GW. Impact of Smoking on Outcomes of Patients With ST-Segment Elevation Myocardial Infarction (from the HORIZONS-AMI Trial). The American Journal Of Cardiology 2011, 108: 1387-1394. PMID: 21864816, DOI: 10.1016/j.amjcard.2011.06.063.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryAntithrombinsCoronary AngiographyCoronary RestenosisCoronary ThrombosisDrug Therapy, CombinationDrug UtilizationFemaleHemorrhageHeparinHirudinsHumansMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionPaclitaxelPeptide FragmentsPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexPyridinesRecombinant ProteinsSmokingStentsConceptsGlycoprotein IIb/IIIa inhibitorsST-segment elevation myocardial infarctionElevation myocardial infarctionPrimary percutaneous coronary interventionProbable stent thrombosisPercutaneous coronary interventionUnfractionated heparinStent thrombosisMajor bleedingMyocardial infarctionBivalirudin monotherapyCoronary interventionSmoking statusPaclitaxel-eluting stent implantationIIb/IIIa inhibitorsAlternative antithrombotic regimensHORIZONS-AMI trialOutcomes of patientsImpact of smokingPaclitaxel-eluting stentsBare metal stentsLate stent thrombosisAntithrombotic regimensIschemic eventsIndependent predictors
2010
Impact of Bivalirudin Therapy in High-Risk Patients With Acute Myocardial Infarction 1-Year Results From the HORIZONS-AMI (Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction) Trial
Parodi G, Antoniucci D, Nikolsky E, Witzenbichler B, Guagliumi G, Peruga JZ, Stuckey T, Dudek D, Kornowski R, Hartmann F, Lansky AJ, Mehran R, Stone GW. Impact of Bivalirudin Therapy in High-Risk Patients With Acute Myocardial Infarction 1-Year Results From the HORIZONS-AMI (Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction) Trial. JACC Cardiovascular Interventions 2010, 3: 796-802. PMID: 20723849, DOI: 10.1016/j.jcin.2010.05.009.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAgedAngioplasty, Balloon, CoronaryAntibodies, MonoclonalAntithrombinsChi-Square DistributionEptifibatideEuropeFemaleFibrinolytic AgentsHemorrhageHeparinHirudinsHumansImmunoglobulin Fab FragmentsIsraelKaplan-Meier EstimateMaleMiddle AgedMyocardial InfarctionPatient SelectionPeptide FragmentsPeptidesPlatelet Aggregation InhibitorsProspective StudiesRecombinant ProteinsRisk AssessmentRisk FactorsSecondary PreventionStentsTime FactorsTreatment OutcomeUnited StatesConceptsGlycoprotein IIb/IIIa inhibitorsHORIZONS-AMI trialHigh-risk patientsAcute myocardial infarctionRecurrent myocardial infarctionUnfractionated heparinMyocardial infarctionHigh riskPrimary percutaneous coronary interventionIIb/IIIa inhibitorsBaseline patient riskCADILLAC risk scoreIntermediate-risk groupPrimary percutaneous interventionPercutaneous coronary interventionHigh-risk groupLow-risk groupBivalirudin therapyMajor bleedingTrial patientsCoronary interventionIntermediate riskClinical variablesPercutaneous interventionPatient riskImpact of Anemia on Clinical Outcomes of Patients With ST-Segment Elevation Myocardial Infarction in Relation to Gender and Adjunctive Antithrombotic Therapy (from the HORIZONS-AMI Trial)
Tsujita K, Nikolsky E, Lansky AJ, Dangas G, Fahy M, Brodie BR, Dudek D, Möckel M, Ochala A, Mehran R, Stone GW. Impact of Anemia on Clinical Outcomes of Patients With ST-Segment Elevation Myocardial Infarction in Relation to Gender and Adjunctive Antithrombotic Therapy (from the HORIZONS-AMI Trial). The American Journal Of Cardiology 2010, 105: 1385-1394. PMID: 20451683, DOI: 10.1016/j.amjcard.2010.01.001.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnemiaAngioplasty, Balloon, CoronaryCombined Modality TherapyDrug Therapy, CombinationElectrocardiographyFemaleFibrinolytic AgentsFollow-Up StudiesHeparinHirudinsHospital MortalityHumansMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionNeoadjuvant TherapyPeptide FragmentsPlatelet Glycoprotein GPIIb-IIIa ComplexProbabilityProportional Hazards ModelsRecombinant ProteinsRisk AssessmentSex FactorsSurvival AnalysisThrombolytic TherapyTreatment OutcomeConceptsST-elevation myocardial infarctionElevation myocardial infarctionGlycoprotein IIb/IIIa inhibitorsPrimary percutaneous coronary interventionIIb/IIIa inhibitorsBaseline anemiaPercutaneous coronary interventionAdjunctive antithrombotic therapyMajor bleedingMyocardial infarctionAntithrombotic therapyCoronary interventionUnfractionated heparinST-segment elevation myocardial infarctionMultivariate analysisAcute Myocardial Infarction trialImpact of anemiaMyocardial Infarction trialOutcomes of patientsHarmonizing OutcomesCardiac mortalityCause mortalityLate mortalityPrimary PCIClinical outcomes
2009
Outcomes of Patients with Coronary Artery Perforation Complicating Percutaneous Coronary Intervention and Correlations with the Type of Adjunctive Antithrombotic Therapy: Pooled Analysis from REPLACE‐2, ACUITY, and HORIZONS‐AMI Trials
DOLL JA, NIKOLSKY E, STONE GW, MEHRAN R, LINCOFF AM, CAIXETA A, MCLAURIN B, CRISTEA E, FAHY M, KESANAKURTHY V, LANSKY AJ. Outcomes of Patients with Coronary Artery Perforation Complicating Percutaneous Coronary Intervention and Correlations with the Type of Adjunctive Antithrombotic Therapy: Pooled Analysis from REPLACE‐2, ACUITY, and HORIZONS‐AMI Trials. Journal Of Interventional Cardiology 2009, 22: 453-459. PMID: 19702677, DOI: 10.1111/j.1540-8183.2009.00494.x.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnticoagulantsChemotherapy, AdjuvantCoronary VesselsDrug Therapy, CombinationFemaleFibrinolytic AgentsHeparinHirudinsHumansMaleMiddle AgedMyocardial InfarctionMyocardial RevascularizationPeptide FragmentsPlatelet Glycoprotein GPIIb-IIIa ComplexRecombinant ProteinsSurvival RateTreatment OutcomeWounds, PenetratingConceptsPercutaneous coronary interventionGP IIb/IIIa inhibitorsIIb/IIIa inhibitorsAdjunctive antithrombotic therapyUnfractionated heparinMyocardial infarctionAntithrombotic therapyCoronary interventionPCI trialProvisional glycoprotein (GP) IIb/IIIa inhibitionGlycoprotein IIb/IIIa inhibitionIIb/IIIa inhibitionBaseline creatinine clearanceHORIZONS-AMI trialGP IIb/IIIaOutcomes of patientsOnly independent predictorCoronary artery perforationManagement of patientsTreatment of patientsIIb/IIIaLower ratesSimilar ratesBivalirudin monotherapyHORIZONS-AMI
2008
Safety and Efficacy of Bivalirudin With and Without Glycoprotein IIb/IIIa Inhibitors in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention 1-Year Results From the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) Trial
White HD, Ohman EM, Lincoff AM, Bertrand ME, Colombo A, McLaurin BT, Cox DA, Pocock SJ, Ware JA, Manoukian SV, Lansky AJ, Mehran R, Moses JW, Stone GW. Safety and Efficacy of Bivalirudin With and Without Glycoprotein IIb/IIIa Inhibitors in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention 1-Year Results From the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) Trial. Journal Of The American College Of Cardiology 2008, 52: 807-814. PMID: 18755342, DOI: 10.1016/j.jacc.2008.05.036.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAdultAgedAged, 80 and overAngioplasty, Balloon, CoronaryAnticoagulantsDrug Therapy, CombinationEnoxaparinFemaleFibrinolytic AgentsHeparinHirudinsHumansMaleMiddle AgedPeptide FragmentsPlatelet Glycoprotein GPIIb-IIIa ComplexRecombinant ProteinsRisk FactorsTime FactorsConceptsIIb/IIIa inhibitorsPercutaneous coronary interventionGlycoprotein IIb/IIIa inhibitorsGP IIb/IIIa inhibitorsHigh-risk ACS patientsImpact of bivalirudinUnfractionated heparinACUITY trialComposite ischemiaACS patientsCoronary interventionAcute coronary syndrome patientsEfficacy of bivalirudinLess major bleedingSimilar ischemic outcomesAcute coronary syndromeCoronary syndrome patientsBivalirudin monotherapyIschemic outcomesMajor bleedingCoronary syndromeSyndrome patientsBivalirudinPatientsEnoxaparinThe Harmonizing Outcomes with RevascularIZatiON and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial: Study design and rationale
Mehran R, Brodie B, Cox DA, Grines CL, Rutherford B, Bhatt DL, Dangas G, Feit F, Ohman EM, Parise H, Fahy M, Lansky AJ, Stone GW. The Harmonizing Outcomes with RevascularIZatiON and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial: Study design and rationale. American Heart Journal 2008, 156: 44-56. PMID: 18585496, DOI: 10.1016/j.ahj.2008.02.008.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAngioplasty, Balloon, CoronaryAnticoagulantsCombined Modality TherapyCoronary AngiographyDose-Response Relationship, DrugDrug Administration ScheduleDrug-Eluting StentsFollow-Up StudiesHeparin, Low-Molecular-WeightHirudinsHumansMaleMiddle AgedMyocardial InfarctionPeptide FragmentsPlatelet Glycoprotein GPIIb-IIIa ComplexProbabilityProspective StudiesRecombinant ProteinsReference ValuesResearch DesignRisk AssessmentStentsSurvival RateThrombosisTime FactorsConceptsPrimary PCIPrimary percutaneous coronary interventionIIb/IIIa inhibitorsAcute myocardial infarctionBare metal stentsGP IIb/IIIa inhibitorsHORIZONS-AMI trialUnfractionated heparinGlycoprotein IIb/IIIa inhibitorsIdentical bare-metal stentOverall event-free survivalAcute Myocardial Infarction trialEnd pointDirect thrombin inhibitor bivalirudinRoutine useEfficacy end pointMyocardial Infarction trialTarget lesion revascularizationEvent-free survivalClinical end pointsPercutaneous coronary interventionPaclitaxel-eluting stentsNew pharmacologic agentsThrombin inhibitor bivalirudinDrug-eluting stents
2007
Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial
Stone GW, White HD, Ohman EM, Bertrand ME, Lincoff AM, McLaurin BT, Cox DA, Pocock SJ, Ware JH, Feit F, Colombo A, Manoukian SV, Lansky AJ, Mehran R, Moses JW, investigators F. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. The Lancet 2007, 369: 907-919. PMID: 17368152, DOI: 10.1016/s0140-6736(07)60450-4.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAngioplasty, Balloon, CoronaryAnticoagulantsCombined Modality TherapyDrug Therapy, CombinationEnoxaparinFemaleHeparinHirudinsHumansMaleMiddle AgedMyocardial IschemiaPeptide FragmentsPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexProspective StudiesRecombinant ProteinsTreatment OutcomeConceptsGlycoprotein IIb/IIIa inhibitorsIIb/IIIa inhibitorsPercutaneous coronary interventionAcute coronary syndromeNet clinical outcomeHigh-risk acute coronary syndromesUrgent Intervention Triage Strategy (ACUITY) trialCoronary interventionClinical outcomesMajor bleedingCoronary syndromeAcute CatheterizationStrategy trialDirect thrombin inhibitor bivalirudinAdverse ischemic eventsMajor haemorrhagic complicationsComparable clinical outcomesThrombin inhibitor bivalirudinHaemorrhagic complicationsIschemic eventsUnfractionated heparinSubgroup analysisProportion of individualsBivalirudinBleeding
2004
Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: Design and rationale of the SYNERGY Library
Petersen JL, Mahaffey KW, Becker RC, Goodman SG, Kleiman NS, Marian AJ, Stone GW, Lansky AJ, Lincoff AM, Hazen SL, Nessel CC, Toro-Figueroa L, Tate L, Reist CJ, Cohen M, Califf RM, Ferguson JJ. Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: Design and rationale of the SYNERGY Library. American Heart Journal 2004, 148: 269-276. PMID: 15308996, DOI: 10.1016/j.ahj.2004.03.022.Peer-Reviewed Original ResearchConceptsAcute coronary syndromeHigh-risk patientsCoronary syndromeClinical trialsGlycoprotein IIb/IIIa Inhibitors (SYNERGY) trialSegment elevation acute coronary syndromesElevation acute coronary syndromeCore laboratory facilityEffect of enoxaparinCardiovascular clinical trialsNovel pharmacologic targetsHigh-risk conditionsFurther drug developmentSYNERGY patientsInflammatory markersInhibitor trialsMulticenter trialCoronary arteriogramsUnfractionated heparinPatient populationMyocardial infarctionCoagulation studiesPharmacologic targetPatientsEnoxaparin
1998
Heparin dosing in patients undergoing coronary intervention
Popma J, Prpic R, Lansky A, Piana R. Heparin dosing in patients undergoing coronary intervention. The American Journal Of Cardiology 1998, 82: 19p-24p. PMID: 9809888, DOI: 10.1016/s0002-9149(98)00759-0.Peer-Reviewed Original ResearchConceptsIIb/IIIa inhibitorsCoronary interventionHeparin therapyHemochron devicePlatelet glycoprotein IIb/IIIa inhibitorsGlycoprotein IIb/IIIa inhibitorsGP IIb/IIIa inhibitorsUncomplicated coronary interventionsWeight-adjusted heparinAntithrombotic regimenHemoTec deviceHeparin bolusHeparin dosingSufficient heparinHeparin administrationConventional heparinUnfractionated heparinSignificant thrombocytopeniaPatientsACT levelsHeparinLonger durationTarget ACTInterventionAnticoagulation